Bioengineering fills new CEO position after Group takeover
With Jiang Pei, the Board of Directors is relying on a Morimatsu Group insider to strengthen the Swiss site in the long term
Advertisement
Bioengineering AG announced the appointment of Mr. Jiang Pei as the new Chief Executive Officer (CEO) at its Board of Directors meeting. The appointment took effect on April 13, 2026.
Bioengineering AG was acquired by the Morimatsu Group, an international engineering company, in September 2025. As a result of this acquisition, the Board of Directors has filled the strategically important position of CEO. The aim is to ensure continuity in the company's management, promote the sustainable development of the company and ensure its successful long-term integration into the international Morimatsu Group.
Mr. Jiang Pei has more than 30 years of international industry experience and has held senior management positions within the Morimatsu Group for many years. His expertise includes the design, manufacture and implementation of complex, customized systems and equipment for demanding industrial applications, especially in highly regulated and technologically sensitive areas such as the pharmaceutical, cosmetics, food and chemical industries.
Throughout his many years of professional experience, Mr. Jiang has acquired extensive technical and commercial expertise in bioengineering, hygienic design and aseptic process control. He also has in-depth knowledge of international quality standards, regulatory frameworks and global project management.
The Board of Directors of Bioengineering AG stated: "With the appointment of Mr. Jiang Pei, we are confident that Bioengineering AG will be led by a highly experienced leader with deep industry knowledge and a profound understanding of the Morimatsu Group. His many years of management experience, his strategic vision and his global perspective make him particularly well suited to lead the company into the next phase of its development."
Mr. Jiang Pei has been working closely with international subsidiaries and leading industry partners worldwide for many years. He is a native Chinese speaker and speaks English, which enables effective communication and leadership at international management level within a global organizational structure.
The Board of Directors added: "The appointment of Mr. Jiang ensures continuity and stability after the takeover and strengthens the position of Bioengineering AG within the Group. We are convinced that under his leadership the company will continue its sustainable development, further strengthen the Swiss site and at the same time make a significant contribution to the international growth of the Morimatsu Group."
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department people
